Un Israélien atteint de la maladie d'Alzheimer précoce développe un traitement potentiel pour la maladie de Parkinson
Initialement éconduit, Ofer Shina a bâti X-tosis autour des recherches de la professeure Varda Shoshan-Barmatz. La start-up bénéficie d'une subvention de 2,74 millions de dollars de la Fondation Michael J. Fox et cible d'abord la…
Évaluation
An Israeli man diagnosed with early-onset Alzheimer's channeled his condition into building a biotech startup rather than accepting a dead end. X-tosis, built on academic research from Prof. Varda Shoshan-Barmatz, now holds a $2.74 million grant from the Michael J. Fox Foundation. The company is initially aiming at Parkinson's disease, not Alzheimer's. The personal stake here is unusually direct: the founder is developing a treatment while living with a related neurodegenerative condition. Watch whether X-tosis can move from grant-funded research to clinical trials, and whether the same mechanism might eventually apply back to Alzheimer's.

